Skip to main content
Premium Trial:

Request an Annual Quote

BD Bioscience, Moving Deeper Into High-content Cell Analysis, Licenses IP from Cellomics

NEW YORK, Nov. 9 (GenomeWeb News) - Cellomics has given Becton Dickinson's BD Bioscience division non-exclusive, worldwide rights to its core high content-screening patent portfolio, the firms said today.

 

The license gives BD Bioscience broad claims to Cellomics' HCS technology and "specific classes" of HCS assays, such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization, the companies said. 

 

BD Bioscience said the move is aimed at further positioning it into the area of high-content cellular analysis, emphasized by the company's acquisition of Atto Bioscience in July.

 

The Cellomics deal was also designed to bolster BD's capabilities in live cell research, which includes high-resolution imaging, flow cytometry, and reagent systems, Mark Lewis, vice president of BD Biosciences, said in a statement.

 

Financial details of the agreement were not disclosed.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.